Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on LinkedIn:
“On Friday, the FDA approved rusfertide, the first-in-class hepcidin mimetic for the treatment of erythrocytosis in adults with polycythemia vera (PV).
What makes this approval particularly interesting is the biology. Although erythrocytosis in PV is driven by constitutive JAK2 signaling, erythropoiesis remains dependent on iron.
Rusfertide mimics the activity of hepcidin, targeting ferroportin and restricting the movement of iron into the circulation.
The resulting reduction in iron availability for erythropoiesis provides a fundamentally different way to control hematocrit, one based on regulating iron trafficking rather than directly suppressing the malignant clone.
In the phase 3 VERIFY trial, which enrolled 293 patients requiring frequent phlebotomy despite standard-of-care therapy, 76.9% of patients receiving rusfertide avoided meeting criteria for phlebotomy during weeks 20–32, compared with 32.9% receiving placebo. Treatment also reduced phlebotomy burden and improved hematocrit control.
For patients living with PV and the cumulative burden of repeated phlebotomy, this creates an entirely new therapeutic axis.
It is also an elegant example of translational hematology: understanding the physiology that sustains a malignant phenotype can identify therapeutic vulnerabilities downstream of the initiating mutation.
Important questions remain, including how rusfertide will be integrated with cytoreductive therapies and, importantly, whether improved hematocrit control via this mechanism ultimately translates into reductions in thrombosis or changes in disease trajectory.
Those outcomes have not yet been established.
Nevertheless, this is a meaningful advance for patients with polycythemia vera and a fascinating validation of the hepcidin–ferroportin axis as a therapeutic target.”
Other posts featuring Nathan Connel on Hemostasis Today.
-
Sep 4, 2026, 02:44Ahmed Kotb: Emergency Management of Critical Bleeding in ITP
-
Sep 4, 2026, 02:30Mario Jimenez: KDIGO 2026 – A More Proactive Approach to IV Iron in Hemodialysis
-
Sep 4, 2026, 02:18Edgardo Alania: Edoxaban in Intracranial Haemorrhage Survivors with AF
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
-
Sep 3, 2026, 20:29Sarah Robins: Happy to Share This Portrait Film I Voiced for the NNHHF
-
Sep 3, 2026, 20:27Mireille Muller: Europe Needs More Plasma Donors
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide